A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.
- 1 August 1988
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 6 (8), 1328-1334
- https://doi.org/10.1200/jco.1988.6.8.1328
Abstract
We report a phase I clinical investigation of 30-minute and four-hour intravenous (IV) infusions of recombinant tumor necrosis factor (rTNF)-alpha. Thirty-nine patients with disseminated cancer received escalating doses of rTNF-alpha for five consecutive days every 2 weeks for a total duration of 8 weeks. Dose escalations followed a modified Fibonacci scale with a minimum of four patients entered at each dose level: 5, 10, 25, 50, 75, 100, 150, 200, and 250 micrograms/m2/d. Toxicities consisted mainly of constitutional symptoms including fever, chills, headache, and fatigue, increasing in severity with dose escalation. No significant differences in dose-limiting toxicities were seen between the two rates of IV infusion. The maximum tolerated dose (MTD) was 200 micrograms/m2 with dose limiting toxicity being constitutional symptoms and hypotension. Hematologic changes included median decrease in both granulocyte and platelet counts of 38% and 41%, respectively (range, 16% to 85%), although clinically significant granulocytopenia and thrombocytopenia were not observed. Hematological parameters returned to baseline within 72 hours after rTNF-alpha was stopped. rTNF-alpha induced changes in lipid metabolism were manifested by median fasting triglyceride elevations above baseline (median, 103 micrograms/dL) of 157% (range, 16% to 389%) after five days of therapy with doses greater than 75 micrograms/m2, associated with a median increase in very-low-density lipoprotein (VLDL) of 80%. Serum rTNF peak levels exceeding 10 ng/mL were observed 30 minutes following rTNF-alpha infusions at MTD dose. Twelve of 34 patients had no change in their evaluable disease for a median duration of 18 weeks (range, 8 to 30 weeks), and 22 patients showed progressive disease. This study forms the framework for phase II trials of IV administered rTNF-alpha.This publication has 10 references indexed in Scilit:
- PHASE-I STUDY OF RECOMBINANT TUMOR-NECROSIS-FACTOR IN CANCER-PATIENTS1987
- Recombinant gamma interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients.The Journal of Experimental Medicine, 1986
- Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.The Journal of Experimental Medicine, 1986
- Lipopolysaccharide-treated RAW 264.7 cells produce a mediator that inhibits lipoprotein lipase in 3T3-L1 cells.The Journal of Immunology, 1985
- Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line.Journal of Biological Chemistry, 1985
- Human tumor necrosis factor. Production, purification, and characterization.Journal of Biological Chemistry, 1985
- Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activityNature, 1984
- Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude miceInternational Journal of Cancer, 1984
- Inhibition of the growth and differentiation of erythroid precursor cells by an endotoxin-induced mediator from peritoneal macrophages.Proceedings of the National Academy of Sciences, 1983
- Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells.Proceedings of the National Academy of Sciences, 1982